Journals / Eurasian Journal of Medicine / 2022 / Cilt: 54 - Sayı: 1

Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass

Pages
92–100
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Alternative agents are also able to restore vascular tone and improve vasoplegia, including methylene blue, angiotensin II, hydroxocobalamin, and ascorbic acid; however, their effect on patient outcomes is still unclear.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vasoplegia is defined by hypotension and low systemic vascular resistance despite the normal or elevated cardiac index, a complication frequently following cardiac surgery, carrying high morbidity and mortality rate.
📊
Key Findings & Data:Vasoplegia is related with a profound systemic inflammatory response and is mainly mediated by cellular hyperpolarization, a relative vasopressin deficiency, and high levels of inducible nitric oxide, following cardiopulmonary bypass.
💡
Conclusion & Impact:Alternative agents are also able to restore vascular tone and improve vasoplegia, including methylene blue, angiotensin II, hydroxocobalamin, and ascorbic acid; however, their effect on patient outcomes is still unclear.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Vasoplegia is defined by hypotension and low systemic vascular resistance despite the normal or elevated cardiac index, a complication frequently following cardiac surgery, carrying high morbidity and mortality rate. Vasoplegia is related with a profound systemic inflammatory response and is mainly mediated by cellular hyperpolarization, a relative vasopressin deficiency, and high levels of inducible nitric oxide, following cardiopulmonary bypass. Cardiopulmonary bypass is a distinct precipitant of vasoplegia, generally due to its association with nitric oxide production and severe vasopressin depletion. Postoperative vasoplegia is usually managed with vasopressors, of which catecholamines are the traditional agents of choice. Recent studies promote the use of non-catecholamine vasopressor (vasopressin) in restoring systemic vascular resistance. Alternative agents are also able to restore vascular tone and improve vasoplegia, including methylene blue, angiotensin II, hydroxocobalamin, and ascorbic acid; however, their effect on patient outcomes is still unclear.

🔖

Cite This Article

MUHAMMAD, R., DHARMADJATI, B. B., MULIA, E. P. B., RACHMI, D. A. (2022). Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass. Eurasian Journal of Medicine, Cilt: 54 - Sayı: 1, 92–100. https://ajindex.com/articles/508789

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Lambden S, Creagh-Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. Crit Care. 2018;22(1):174. [CrossRef]
  2. Shaefi S, Mittel A, Klick J, et al. Vasoplegia After cardiovascular procedures—pathophysiology and targeted therapy. J Cardiothorac Vasc Anesth. 2018;32(2):1013-1022. [CrossRef]
  3. Omar S, Zedan A, Nugent K. Cardiac Vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sci. Januarie. 2015;349(1):80- 88. [CrossRef] 4. Charles FG, Murray LJ, Giordano C, Spiess BD. Vitamin B12 for the treatment of vasoplegia in cardiac surgery and liver transplantation: a narrative review of cases and potential biochemical mechanisms. Can J Anaesth. 2019;66(12):1501- 1513. [CrossRef] 5. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. Epstein FH, redakteur. N Engl J Med. 2001;345(8):588-595. [CrossRef] 6. Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options. Crit Care. 2020;24(1):36. [CrossRef] 7. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-810. [CrossRef] 8. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116(6):973-980. [CrossRef] 9. Dayan V, Cal R, Giangrossi F. Risk factors for vasoplegia after cardiac surgery: a meta-analysis. Interact Cardiovasc Thorac Surg. 2019;28(6):838- 844. [CrossRef] 10. Travieso-Gonzalez A, Núñez-Gil IJ, Riha H, Donaire JAG, Ramakrishna H. Management of arterial hypertension: 2018 ACC/AHA Versus ESC guidelines and perioperative implications. J Cardiothorac Vasc Anesth. 2019;33(12):3496- 3503. [CrossRef] 11. Cameron D. Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. J Cardiovasc Pharmacol. 1996;27(suppl 1):S1-S5. [CrossRef] 12. Fischer GW, Levin MA. Vasoplegia During cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg. 2010;22(2):140- 144. [CrossRef] 13. Braunwald E, Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia: Elsevier Inc. bl; 2019:1944
  4. Morciano G, Bonora M, Campo G, et al. Mechanistic role of mPTP in ischemia-reperfusion injury. Adv Ex